---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-015447"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:57:17.819917+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M

## Summary
- Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.
- Net loss narrowed to $3.8M ($0.08/sh) from $8.3M loss; non-GAAP adjusted EBITDA $7.8M (20% margin).
- Full-year 2021 revenue guidance raised to $168-171M; adjusted EBITDA margin guided to 23%-25%.
- Record quarterly MACI biopsies and Epicel grafting; MACI biopsies up >50% in H1 2021 vs H1 2020.
- Cash and investments $116M, no debt; operating cash flow $4.8M in Q2.

## SEC filing metadata
- accession: 0001628280-21-015447
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/0001628280-21-015447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828021015447/vcel-20210804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-015447
- JSON: https://secwatch.observer/filing/0001628280-21-015447.json
- Plain text: https://secwatch.observer/filing/0001628280-21-015447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.